Aurobindo's injectable business grows 8% year-on-year to $50 mn in Q2

Analysts feel R&D costs are set to rise as a result of injectables and biosimilars focus

Hyderabad-headquartered Aurobindo Pharmaceuticals, which draws around 47 per cent of its revenues from the US, is a late entrant in the biosimilars and injectables space. While it now expects its first biosimilar product approval to come in the next 12-18 months, it has already enhanced its focus to growing its injectables business in the US. 

In the second quarter, AuroMedics, the company's injectable business, witnessed an 8 per cent year-on-year growth to $50 million. The company has already filed a total of 104 injectables, abbreviated new drug applications (ANDAs), as of September 30. Of these, 59 have received final approval